Hamaton Automotive Technology Co., Ltd (SHE:300643)

Ligand Pharmaceuticals Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Jan 1, 2024	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	1,067	1,078	1,062	1,061	1,016	786.01
Other Revenue	5.56	5.56	5.4	8.02	7.14	2.64
Revenue	1,072	1,083	1,068	1,069	1,023	788.65
Revenue Growth (YoY)	-2.92%	1.48%	-0.16%	4.55%	29.70%	71.90%
Cost of Revenue	704.77	714.55	740.27	737.41	715.07	570.29
Gross Profit	367.54	368.91	327.35	331.96	307.8	218.36
Selling, General & Admin	182.34	183.67	156.07	146.59	139.3	141.45
Research & Development	44.42	46.57	53.34	42.3	41.65	34.44
Other Operating Expenses	9.46	5.29	5.9	3.99	3.18	2.81
Operating Expenses	236.59	236.87	215.61	192.25	187.94	178.81
Operating Income	130.96	132.04	111.74	139.71	119.86	39.54
Interest Expense	-	-3.89	-5.35	-5.14	-5.86	-5.89
Interest & Investment Income	5.35	6.14	10.54	2.27	2.27	2.04
Currency Exchange Gain (Loss)	6.13	6.13	9.28	17.75	1.86	-8.24
Other Non Operating Income (Expenses)	0.77	-2.34	-0.67	-1.19	-1.63	-0.96
EBT Excluding Unusual Items	143.21	138.07	125.55	153.4	116.5	26.49
Gain (Loss) on Sale of Investments	0.54	0.36	-0.56	1.78	1.69	1.19
Gain (Loss) on Sale of Assets	0.27	0.27	0.09	0.34	0.48	-0.29
Asset Writedown	0.11	-0.02	-0.01	-0.13	-0.31	0.04
Other Unusual Items	5.83	4.12	7.33	9.17	7.02	19.05
Pretax Income	149.96	142.81	132.41	164.57	125.39	46.49
Income Tax Expense	16.23	17.4	9.18	25.53	13.03	9.47
Earnings From Continuing Operations	133.73	125.4	123.23	139.04	112.36	37.02
Minority Interest in Earnings	-0.25	-1.78	-3.41	-5.29	-2.1	-0.66
Net Income	133.47	123.62	119.82	133.76	110.26	36.36
Net Income to Common	133.47	123.62	119.82	133.76	110.26	36.36
Net Income Growth	1.15%	3.17%	-10.42%	21.32%	203.24%	83.30%
Shares Outstanding (Basic)	230	229	230	231	212	202
Shares Outstanding (Diluted)	230	229	230	231	212	202
Shares Change (YoY)	-1.38%	-0.65%	-0.08%	8.77%	4.97%	1.84%
EPS (Basic)	0.58	0.54	0.52	0.58	0.52	0.18
EPS (Diluted)	0.58	0.54	0.52	0.58	0.52	0.18
EPS Growth	2.57%	3.85%	-10.35%	11.54%	188.89%	80.00%
Free Cash Flow	110.12	138.09	50.03	45.19	12.54	17.64
Free Cash Flow Per Share	0.48	0.60	0.22	0.20	0.06	0.09
Dividend Per Share	0.160	0.160	0.160	0.118	0.088	0.090
Dividend Growth	-	-	35.59%	34.09%	-2.22%	125.00%
Gross Margin	34.28%	34.05%	30.66%	31.04%	30.09%	27.69%
Operating Margin	12.21%	12.19%	10.47%	13.06%	11.72%	5.01%
Profit Margin	12.45%	11.41%	11.22%	12.51%	10.78%	4.61%
Free Cash Flow Margin	10.27%	12.75%	4.69%	4.23%	1.23%	2.24%
EBITDA	186.81	187.05	163.39	185.81	166.36	84.33
EBITDA Margin	17.42%	17.26%	15.30%	17.38%	16.26%	10.69%
D&A For EBITDA	55.85	55.01	51.65	46.1	46.5	44.79
EBIT	130.96	132.04	111.74	139.71	119.86	39.54
EBIT Margin	12.21%	12.19%	10.47%	13.06%	11.72%	5.01%
Effective Tax Rate	10.82%	12.19%	6.93%	15.51%	10.39%	20.37%
Revenue as Reported	1,072	1,083	1,068	1,069	1,023	788.65
Advertising Expenses	-	6.53	3.33	2.82	2.59	0.76

Source: S&P Global Market Intelligence. Standard template. Financial Sources.